Trial
NCT04060147
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Primary Sclerosing Cholangitis
Intervention
Cilofexor
Why stopped
The study enrollment was terminated early by the sponsor due to recruitment challenges.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-27